Recent clinical trials have demonstrated the efficacy of IROX, a combination of Irinotecan and Oxaliplatin, as a second-line therapy for patients with metastatic colorectal cancer (mCRC) who have shown progression after initial treatment. A pivotal phase III trial by Rothenberg et al. (2003) found that the combination of oxaliplatin and fluorouracil–leucovorin was superior to either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil–leucovorin treatment. This finding was supported by Saltz et al. (2000), who reported the benefits of irinotecan plus fluorouracil and leucovorin for mCRC.
Further research by Haller et al. (2008) compared oxaliplatin plus irinotecan with irinotecan alone as a second-line treatment after single-agent fluoropyrimidine therapy for mCRC, reinforcing the advantages of combination therapies. Goldberg et al. (2004) also contributed to this body of evidence with a randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in previously untreated mCRC patients.
Sequential and combination chemotherapy strategies were explored by Seymour et al. (2007) and Koopman et al. (2007), respectively, in patients with poor prognosis advanced colorectal cancer, providing insights into optimal treatment sequences. Additionally, the role of bevacizumab in combination with chemotherapy was highlighted by Hurwitz et al. (2004) and Giantonio et al. (2007), showing improved outcomes in previously treated mCRC patients.
These studies collectively underscore the importance of combination therapies, including IROX, in the management of metastatic colorectal cancer, offering patients improved survival and quality of life.
